These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 30283446)

  • 1. Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy.
    Roszik J; Ring KL; Wani KM; Lazar AJ; Yemelyanova AV; Soliman PT; Frumovitz M; Jazaeri AA
    Front Immunol; 2018; 9():2102. PubMed ID: 30283446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Markers of Angiogenesis, Lymphangiogenesis, and Epithelial-Mesenchymal Transition (Plasticity) in CIN and Early Invasive Carcinoma of the Cervix: Exploring Putative Molecular Mechanisms Involved in Early Tumor Invasion.
    Kurmyshkina O; Kovchur P; Schegoleva L; Volkova T
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor.
    Cocco E; Varughese J; Buza N; Bellone S; Glasgow M; Bellone M; Todeschini P; Carrara L; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Lockwood CJ; Santin AD
    BMC Cancer; 2011 Jun; 11():263. PubMed ID: 21693061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breaking the DNA damage response to improve cervical cancer treatment.
    Wieringa HW; van der Zee AG; de Vries EG; van Vugt MA
    Cancer Treat Rev; 2016 Jan; 42():30-40. PubMed ID: 26643553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unraveling Differences in Molecular Mechanisms and Immunological Contrasts between Squamous Cell Carcinoma and Adenocarcinoma of the Cervix.
    Salarzaei M; van de Laar RLO; Ewing-Graham PC; Najjary S; van Esch E; van Beekhuizen HJ; Mustafa DAM
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenomic Identification for Predicting the Prognosis of Cervical Cancer Patients.
    Wang Q; Vattai A; Vilsmaier T; Kaltofen T; Steger A; Mayr D; Mahner S; Jeschke U; Hildegard Heidegger H
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33671013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prognostic signature based on immune-related genes for cervical squamous cell carcinoma and endocervical adenocarcinoma.
    Liu J; Wu Z; Wang Y; Nie S; Sun R; Yang J; Cheng W
    Int Immunopharmacol; 2020 Nov; 88():106884. PubMed ID: 32795900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioinformatics and in vitro experimental analyses identify the selective therapeutic potential of interferon gamma and apigenin against cervical squamous cell carcinoma and adenocarcinoma.
    Yang PM; Chou CJ; Tseng SH; Hung CF
    Oncotarget; 2017 Jul; 8(28):46145-46162. PubMed ID: 28526810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of DNA damage response proteins in cervical cancer patients treated with radical chemoradiotherapy.
    Ho CK; Kornaga EN; Klimowicz AC; Enwere EK; Dean M; Bebb GD; Phan T; Ghatage P; Magliocco AM; Lees-Miller SP; Doll CM
    Gynecol Oncol; 2017 Apr; 145(1):176-184. PubMed ID: 28131528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant expression of microRNA-26b and its prognostic potential in human cervical cancer.
    Luo M; Shen D; Wang W; Xian J
    Int J Clin Exp Pathol; 2015; 8(5):5542-8. PubMed ID: 26191262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cervical cancer patients that respond to chemoradiation therapy display an intense tumor infiltrating immune profile before treatment.
    Martins PR; Machado CMT; Coxir SA; de Oliveira AJ; Moreira TB; Campos LS; Alcântara R; de Paula SOC; de Oliveira Salles PG; Gollob KJ; Magalhães WCS
    Exp Mol Pathol; 2019 Dec; 111():104314. PubMed ID: 31654628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-125a suppresses tumor growth, invasion and metastasis in cervical cancer by targeting STAT3.
    Fan Z; Cui H; Xu X; Lin Z; Zhang X; Kang L; Han B; Meng J; Yan Z; Yan X; Jiao S
    Oncotarget; 2015 Sep; 6(28):25266-80. PubMed ID: 26389681
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Zhu X; Zhang Y; Bai Y; Gu X; Chen G; Sun L; Wang Y; Qiao X; Ma Q; Zhu T; Bu J; Xue J; Liu C
    Int J Med Sci; 2020; 17(17):2773-2789. PubMed ID: 33162805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The differences in immune features and genomic profiling between squamous cell carcinoma and adenocarcinoma - A multi-center study in Chinese patients with uterine cervical cancer.
    Li J; Xue X; Zhang Y; Ding F; Wu W; Liu C; Xu Y; Chen H; Ou Q; Shao Y; Li X; Wu F; Wu X
    Gynecol Oncol; 2023 Aug; 175():133-141. PubMed ID: 37356314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAK4 confers the malignance of cervical cancers and contributes to the cisplatin-resistance in cervical cancer cells via PI3K/AKT pathway.
    Shu XR; Wu J; Sun H; Chi LQ; Wang JH
    Diagn Pathol; 2015 Sep; 10():177. PubMed ID: 26411419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 expression is associated with tumor infiltrating lymphocytes that predict response to NACT in squamous cell cervical cancer.
    D'Alessandris N; Palaia I; Pernazza A; Tomao F; Di Pinto A; Musacchio L; Leopizzi M; Di Maio V; Pecorella I; Benedetti Panici P; Della Rocca C
    Virchows Arch; 2021 Mar; 478(3):517-525. PubMed ID: 32915266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of elevated SCC-Ag level on tumor recurrence and patient survival in patients with squamous-cell carcinoma of uterine cervix following definitive chemoradiotherapy: a multi-institutional analysis.
    Choi KH; Lee SW; Yu M; Jeong S; Lee JW; Lee JH
    J Gynecol Oncol; 2019 Jan; 30(1):e1. PubMed ID: 30479085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular profiling of tumour budding implicates TGFβ-mediated epithelial-mesenchymal transition as a therapeutic target in oral squamous cell carcinoma.
    Jensen DH; Dabelsteen E; Specht L; Fiehn AM; Therkildsen MH; Jønson L; Vikesaa J; Nielsen FC; von Buchwald C
    J Pathol; 2015 Aug; 236(4):505-16. PubMed ID: 25925492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of driver genes regulating immune cell infiltration in cervical cancer by multiple omics integration.
    Wen Y; Zhang S; Yang J; Guo D
    Biomed Pharmacother; 2019 Dec; 120():109546. PubMed ID: 31675687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Target-based molecular signature characteristics of cervical adenocarcinoma and squamous cell carcinoma.
    Kim YW; Bae SM; Kim YW; Park DC; Lee KH; Liu HB; Kim IW; Jang CK; Ahn WS
    Int J Oncol; 2013 Aug; 43(2):539-47. PubMed ID: 23707988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.